As an innovative antibody development engine under Cyagen, the AbSeek™ is specifically designed to accelerate the development of antibody drugs. Leveraging nearly two decades of expertise in life sciences from Cyagen, AbSeek™ integrates artificial intelligence (AI) and bioinformatics to offer a comprehensive, one-stop intelligent solution covering the entire process of antibody discovery, optimization, and validation. It empowers researchers to overcome traditional R&D bottlenecks and press the "fast-forward" button on new drug development.
Why Choose AbSeek™?
Full-Process Intelligence
Centering around AI, AbSeek™ integrates over 20 proprietary and open-source tools that cover key stages such as antibody sequence analysis, structure prediction, affinity optimization, and immunogenicity assessment. Whether it’s rapid screening of antibody candidates or optimizing antibody function through deep learning, AbSeek™ can always simplify complex computations, driving antibody design from experience-based to data-driven intelligence.
AbSeek™ adopts advanced deep learning techniques and proprietary models, leading to its high accuracy and efficiency. Through continuous iteration, AbSeek™ now can analyze massive volumes of antibody data and deliver clear, reliable results for decision-making.
User-Friendly & Accessible
Tailored for antibody research scenarios, AbSeek™ features a clean and intuitive user interface with support for both Chinese and English, complemented by detailed tutorials and case libraries for quick onboarding. In addition, our platform uses visualization modules to transform complex data into intuitive charts, enabling efficient insights.
We take data privacy seriously. With enterprise-level encryption and privacy protection protocols, AbSeek™ ensures your research remains protected at all times.
AI Meets Biology: A Closed-Loop R&D Ecosystem
AbSeek™ works hand-in-hand with Cyagen’s proprietary HUGO-Ab® fully human antibody mouse, creating a seamless “AI Design → Animal Validation” workflow. Our HUGO-Ab® mouse carries complete human immunoglobulin genes, capable of generating fully humanized antibodies with high affinity and low immunogenicity. Their combination dramatically shortens the path from bench to badside, accelerating your new drug commercialization.
About Cyagen
Established in 2006, Cyagen is a national high-tech enterprise and a recognized “Specialized, Refinement, Specialty, and Innovation (SRSI) Little Giant” in China, committed to providing world-class models and innovative services for global life sciences. As a global leader in animal model generation and gene editing technologies, Cyagen serves researchers and pharmaceutical companies in over 100 countries.
Our integrated ecosystem includes:
- Smart Animal Models
- High-Throughput Cell Engineering
- Drug Evaluation Platforms
With more than 900 employees, 40,000+ square meters of R&D space, and offices in China, the U.S., and Japan, Cyagen supports breakthroughs across oncology, gene therapy, nucleic acid drugs, and antibody development. Our work has contributed to over 13,000 scientific publications, including top-tier journals such as Cell, Nature, and Science. At Cyagen, our mission is simple: "Creating Limitless Possibilities for Life Sciences." With AbSeek™, we continues to drive industry innovation and builds a healthier future alongside global partners.
Shape the Future of Drug Discovery with Antibody
